Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- It’s Not the Right Time to Conduct Drug Price Survey for Off-Year Re-Pricing: JPMA Chief
June 18, 2020
- Japan Biotech Group Submits Request to Health Minister on Coronavirus-Tied Development
June 17, 2020
- Nearly 80% of Clinics See Increase in Long-Term Prescriptions amid COVID-19: JMA Survey
June 15, 2020
- Opinion Reflected to Certain Degree for Comparator PMP Deduction Rule: FPMAJ
June 12, 2020
- Impact of Off-Year Drug Re-Pricing Should Be Limited: FPMAJ
June 12, 2020
- Eisai’s Akana Elected as New Chair of FPMAJ’s Drug Pricing Committee
June 12, 2020
- New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
June 12, 2020
- 3 Healthcare Organizations Prod Govt to Forgo FY2020 Drug Price Survey
June 11, 2020
- Postpone Off-Year Drug Re-Pricing Until 2023 or Beyond: JPMA
June 11, 2020
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
- Patient Advocacy Group Urges MLHW to Increase Funding for Pancreatic Cancer Research
June 8, 2020
- API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
- JGA Chief Sawai to Stay in His Post, Deputy Chief Tamura Stepping Down
June 4, 2020
- JPMA Reprimands Torii, Nippon Chemiphar over Price-Fixing
May 29, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- JPWA Resolution Urges Govt to Revisit Off-Year Drug Re-Pricing
May 29, 2020
- Generic/Biosimilar Society Calls on MHLW to Ensure Stable API Supply
May 26, 2020
- Japan Pharmacist Group Renews Opposition to Off-Year Re-Pricing in FY2021
May 22, 2020
- Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
May 21, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…